Wednesday, October 1, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Biology

Researchers Identify Molecular “Switch” Driving Chemoresistance in Blood Cancer

August 15, 2025
in Biology
Reading Time: 4 mins read
0
66
SHARES
598
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

In the relentless battle against cancer, one of the most formidable obstacles remains the ability of malignant cells to evade the effects of chemotherapy, leading to disease relapse and poor patient outcomes. Acute myeloid leukemia (AML), a highly aggressive form of blood cancer accounting for approximately 80% of adult acute leukemia cases, epitomizes this challenge due to its notorious capacity for recurrence after initial treatment success. Recent groundbreaking research spearheaded by scientists at The Jackson Laboratory (JAX) has illuminated a previously elusive molecular mechanism that underpins this chemoresistance, pointing to promising new therapeutic avenues that could transform AML patient care.

At the heart of this research lies a specific protein isoform, RUNX1C, which is a variant product of the RUNX1 gene, known to be a critical regulator of normal blood cell differentiation and function. This isoform had been relatively understudied, but the JAX team, led by assistant professor Eric Wang, has uncovered its pivotal role in enabling AML cells to withstand chemotherapy and enter a protective dormant state. The study, published in the prestigious journal Blood Cancer Discovery, underscores a sophisticated regulatory axis involving RUNX1C and a downstream gene, BTG2, which together orchestrate the quiescence and survival of leukemia cells in the face of genotoxic stress from chemotherapeutic agents.

The investigation employed a comprehensive analysis of patient-derived data, examining samples taken before chemotherapy and after AML relapse. Remarkably, the researchers identified a pronounced increase in DNA methylation—a chemical modification that generally suppresses gene expression—in a genomic region controlling RUNX1. This epigenetic switch led to enhanced production of the RUNX1C isoform specifically, rather than a general increase in RUNX1 expression. This precision epigenetic alteration is critical because it activates a cascade of molecular events that skew the leukemia cells toward chemoresistance.

Delving deeper into mechanism, it was revealed that RUNX1C upregulates the BTG2 gene. BTG2 functions as a cell cycle regulator by interfering with RNA activity, effectively dampening cellular proliferation signals. The consequence is a shift in leukemia cells to enter a quiescent or dormant state, wherein they cease dividing and thus evade the cytotoxic effects of chemotherapy, which preferentially targets rapidly dividing cells. This cellular dormancy effectively cloaks the cancer cells from therapeutic elimination, allowing them to persist silently and ultimately rekindle disease when treatment ceases.

Wang emphasizes the clinical implications of these findings, noting the scarcity of effective treatments for AML patients who relapse following standard chemotherapy regimens. This research not only elucidates the molecular underpinnings of relapse but also identifies RUNX1C as a strategically viable target for therapeutic intervention. Importantly, the team demonstrated that experimentally inhibiting RUNX1C in AML cellular models and mouse systems significantly lowered chemoresistance, as cancer cells were forced out of quiescence, becoming once again vulnerable to chemotherapeutic drugs.

Central to this innovative approach is the application of antisense oligonucleotides (ASOs), sophisticated RNA-targeting molecules capable of binding to specific RNA transcripts and blocking protein production. While ASO technology has seen success in rare neurological disorders, its use in AML and other cancers remains largely unexplored. The promising results from Wang’s lab suggest that ASOs engineered specifically to suppress RUNX1C expression could restore chemotherapy sensitivity by preventing leukemia cells from entering dormancy, offering a potent combination strategy alongside conventional treatments.

The functional experiments conducted by Dr. Cuijuan Han, the study’s lead author, further validated the causative role of RUNX1C in chemoresistance. Overexpression of RUNX1C rendered AML cells resistant to multiple chemotherapeutic drugs, while genetic silencing of this isoform sensitized cells, underscoring a direct link between RUNX1C abundance and therapy outcomes. These meticulously executed gain- and loss-of-function studies highlight the isoform-specific nature of chemoresistance mechanisms, an aspect previously overlooked in AML research.

This work also serves as an important proof of concept that RNA isoforms—which arise from alternative processing of the same gene transcript—are not mere biological noise but critical regulators of cancer cell behavior. Such isoform-specific targeting may revolutionize the understanding and treatment of not only AML but potentially a broad spectrum of cancers. Wang notes the potential to extend these insights, proposing future research to explore isoform modulation across different malignancies and therapeutic contexts.

Beyond its immediate translational potential, this research adds a novel layer to the complex understanding of cancer biology. The epigenetic regulation of gene isoforms introduces a nuanced dimension to how leukemic cells adapt to and resist chemotherapeutic pressure. It shifts the paradigm from focusing solely on gene-level expression changes to appreciating the diversity of RNA isoforms driving disease progression. This enhanced comprehension could inform biomarker development and therapeutic design, optimizing individualized treatment strategies.

The Jackson Laboratory team plans to continue refining RNA-targeting technologies to enhance specificity and efficacy in vivo, as well as to investigate combinational therapies pairing ASOs with emerging targeted agents. They envision that the tailored inhibition of RUNX1C could be integrated into multi-modal treatment regimens, improving remission durability and ultimately patient survival. Given the high relapse rate and dismal prognosis for relapsed AML patients, such advancements could markedly shift clinical outcomes.

In conclusion, the JAX study illuminates a transformative avenue in cancer therapeutics by pinpointing an isoform-specific pathway that governs leukemia cell dormancy and chemoresistance. Through the innovative use of RNA-targeting antisense technology, there is newfound hope for overcoming one of the most stubborn hurdles in AML treatment. This research not only enhances fundamental cancer biology knowledge but also foreshadows the arrival of precision molecular interventions capable of disabling the stealth tactics employed by lethal cancers.


Subject of Research: Animals

Article Title: An Isoform-Specific RUNX1C–BTG2 Axis Governs AML Quiescence and Chemoresistance

News Publication Date: 11-Aug-2025

Web References:

  • https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-24-0327/764069/An-Isoform-Specific-RUNX1C-BTG2-Axis-Governs-AML
  • http://dx.doi.org/10.1158/2643-3230.BCD-24-0327

References:
Wang, E., Han, C., et al. An Isoform-Specific RUNX1C–BTG2 Axis Governs AML Quiescence and Chemoresistance. Blood Cancer Discovery. 11 August 2025.

Image Credits: The Jackson Laboratory

Keywords: Leukemia, Myeloid leukemia, RNA

Tags: acute myeloid leukemia treatment challengesblood cancer patient outcomesBTG2 gene and leukemia survivalcancer cell dormancy and chemotherapycancer research breakthroughs 2023chemoresistance in blood cancerinnovative strategies for AML treatmentJackson Laboratory cancer researchmolecular mechanisms of cancer relapseRUNX1C protein isoform in leukemiatherapeutic targets for AMLunderstanding leukemia cell behavior
Share26Tweet17
Previous Post

Efficient Framework Models Ionic Materials’ Surface Chemistry

Next Post

How Sibling and Friend Playtime Enhances Safety for Children in Online Video Games

Related Posts

blank
Biology

Eco-Friendly Synthesis of Antimicrobial Coumarin Derivatives

October 1, 2025
blank
Biology

Unveiling Phosphate Uptake Genes in Orychophragmus Violaceus

October 1, 2025
blank
Biology

DNA Evidence Fills Critical Gaps in Global Conservation Databases for Amazon Wildlife

October 1, 2025
blank
Biology

Mapping Resilient Dairy Cow Genes: A Cross-Breed Study

October 1, 2025
blank
Biology

Comparative Analysis of Catfish Species in Cage Culture

October 1, 2025
blank
Biology

Decoding the Molecular Mechanisms Behind Long COVID Brain Fog

October 1, 2025
Next Post
blank

How Sibling and Friend Playtime Enhances Safety for Children in Online Video Games

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27561 shares
    Share 11021 Tweet 6888
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    969 shares
    Share 388 Tweet 242
  • Bee body mass, pathogens and local climate influence heat tolerance

    646 shares
    Share 258 Tweet 162
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    513 shares
    Share 205 Tweet 128
  • Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function

    476 shares
    Share 190 Tweet 119
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Sweets Intake Linked to Breast Cancer Risk
  • Astrocyte-Endothelial Cell Dynamics in the Aging Brain: New Insights
  • When Washington Tried to Starve Industries of Loans—and the Plan Backfired
  • Eco-Friendly Synthesis of Antimicrobial Coumarin Derivatives

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,185 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading